TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07121946: This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Sponsor: LTZ Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 42 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,036,728

Rescue Site Savings

+$691,152

Unlock Full NCT07121946 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07121946 Rescue Dossier →